The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A Controlled Trial of Rotigotine Monotherapy in Early Parkinson's Disease
Abstract
BACKGROUND: Oral dopamine agonists are effective for treating early Parkinson's disease (PD). Rotigotine is a dopamine agonist delivered through a silicone-based transdermal patch that is replaced every 24 hours. OBJECTIVES: To assess the efficacy and safety of rotigotine in patients with PD not receiving dopaminergic medications. DESIGN: Randomized, double-blind, placebo-controlled study. Patients Two hundred forty-two patients with early PD. Intervention Treatment with patches containing either 4.5, 9.0, 13.5, or 18.0 mg of rotigotine or placebo for 11 weeks. Main Outcome Measure The change in the sum of the scores of the activities of daily living and motor components of the Unified Parkinson's Disease Rating Scale from baseline to the end of treatment. RESULTS: There was a significant dose-related improvement in the motor and activities of daily living Unified Parkinson's Disease Rating Scale score between baseline and week 11 for the 13.5- and 18.0-mg groups compared with placebo (placebo, 0.3 +/- 7.7; 13.5-mg group, 5.1 +/- 7.0, P =.001; 18.0-mg group, 5.3 +/- 7.0, P<.001). Adverse experiences that occurred more commonly among subjects randomized to active treatment vs placebo included nausea, application site reactions, dizziness, insomnia, somnolence, vomiting, and fatigue. CONCLUSIONS: Rotigotine can be safely administered once daily transdermally and improves parkinsonian signs in patients with early PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Cited by
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Trenkwalder, C., Kies, B., Rudzinska, M., Fine, J., Nikl, J., Honczarenko, K., Dioszeghy, P., Hill, D., Anderson, T., Myllyla, V., et al. (2011) · Movement Disorders · doi:10.1002/mds.23441 · Cited by 437
Poewe, W. H., Rascol, O., Quinn, N., Tolosa, E., Oertel, W. H., Martignoni, E., Rupp, M., & Boroojerdi, B. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70108-4 · Cited by 398
Current approaches to the treatment of Parkinson’s disease
Jankovic, J. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2006 · Cited by 342
Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study
LeWitt, P. A., Lyons, K. E., & Pahwa, R. (2007) · Neurology · doi:10.1212/01.wnl.0000259516.61938.bb · Cited by 261
Metadata
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2003-12-01
- Volume
- 60
- Issue
- 12
- Pages
- 1721
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W4252472226
- Cited by
- 203
- References
- 1
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Controlled Trial of Rotigotine Monotherapy in Early Parkinson's Disease. https://app.cochat.ai/papers/10.1001/archneur.60.12.1721
- The paper
- A Controlled Trial of Rotigotine Monotherapy in Early Parkinson's Disease. (2003). Archives of Neurology. https://doi.org/10.1001/archneur.60.12.1721
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.